中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(1): 64-69

Role of salidroside in a mouse model of non-alcoholic fatty liver disease： A study based on nicotinamide phosphoribosyltransferase

DOI: 10.12449/JCH240112
  • 1.

    Department of Spleen，Stomach and Liver Diseases，Luzhou Hospital of Traditional Chinese Medicine，Luzhou，Sichuan 646000，China

  • 2.

    Department of General Practice，The Affiliated Hospital of Southwest Medical University，Luzhou，Sichuan 646000，China

Research funding:

Southwest Medical University-Luzhou Traditional Chinese Medicine Hospital Base Project (2017-LH012)

  • Received Date: 2023-04-09
  • Accepted Date: 2023-05-26
  • Published Date: 2024-01-23
    Abstract
  •   Objective  To investigate the protective effect of salidroside against nonalcoholic fatty liver disease （NAFLD） and its mechanism of action.  Methods  A total of 24 male KM mice were randomly divided into normal group， HFD group， HFD+blank control group， and HFD+salidroside group， with 6 mice in each group. The mice in the normal group were given normal diet， and those in the other groups were given high-fat diet. After 14 weeks of modeling， the mice were given salidroside 100 mg/kg/day by gavage， and related samples were collected at the end of week 22. Enzyme-linked immunosorbent assay was used to measure the serum levels of related biochemical parameters including alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， triglyceride （TG）， total cholesterol （TC）， high-density lipoprotein cholesterol （HDL-C）， and low-density lipoprotein cholesterol （LDL-C）； HE staining and NAFLD activity score （NAS） were used to observe the liver histopathology of mice； Western blot was used to measure the changes in the expression of NAMPT， Sirt1， AMPKα， and SREBP1 in liver tissue. A one-way analysis of variance was used for comparison between multiple groups， and the least significant difference t-test was used for further comparison between two groups.  Results  Compared with the normal group， the HFD group had obvious steatosis and extensive large lipid droplets in liver tissue， with significant increases in NAS score （P<0.01） and the content of AST， ALT， TG， TC， and LDL-C in peripheral blood （all P<0.05） and a significant reduction in the content of HDL-C （P<0.05）， as well as significant reductions in the expression levels of NAMPT， AMPKα， and Sirt1 in liver tissue （all P<0.05） and a significant increase in the expression level of SERBP1 （P<0.01）. Compared with the HFD group and the HFD+blank control group， the HFD+salidroside group had reductions in the distribution of vacuolar lipid droplets and intralobular inflammation in liver tissue， alleviation of the ballooning degeneration of hepatocytes， significant reductions in NAS score （P<0.01） and the content of AST， ALT， TG， and LDL-C in peripheral blood （all P<0.05）， and a significant increase in the content of HDL-C （P<0.05）， as well as significant increases in the expression levels of NAMPT， AMPKα， and Sirt1 in liver tissue （all P<0.05） and a significant reduction in the expression level of SERBP1 （P<0.01）.  Conclusion  Salidroside can significantly improve the pathological state of mice with NAFLD induced by high-fat diet and exert a protective effect against NAFLD by increasing the expression of NAMPT， Sirt1， and AMPKα and reducing the expression of SERBP1.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    FAN JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J]. J Gastroenterol Hepatol, 2013, 28( Suppl 1): 11- 17. DOI: 10.1111/jgh.12036.
    [2]
    LAZARUS JV, MARK HE, VILLOTA-RIVAS M, et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?[J]. J Hepatol, 2022, 76( 4): 771- 780. DOI: 10.1016/j.jhep.2021.10.025.
    [3]
    YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64( 1): 73- 84. DOI: 10.1002/hep.28431.
    [4]
    CHEN SD, ZHOU HH, ZHAO ZX, et al. Jiangzhi and Hepatoprotective effect of salidroside on nonalcoholic fatty liver disease[J]. China J Tradit Chin Med Pharm, 2013, 28( 9): 2701- 2703.

    陈少东, 周海虹, 赵正晓, 等. 红景天苷对非酒精性脂肪性肝炎的降脂保肝作用研究[J]. 中华中医药杂志, 2013, 28( 9): 2701- 2703.
    [5]
    YANG ZR, WANG HF, ZUO TC, et al. Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats[J]. BMC Pharmacol Toxicol, 2016, 17: 16. DOI: 10.1186/s40360-016-0059-8.
    [6]
    SUN P, SONG SZ, JIANG S, et al. Salidroside regulates inflammatory response in raw 264.7 macrophages via TLR4/TAK1 and ameliorates inflammation in alcohol binge drinking-induced liver injury[J]. Molecules, 2016, 21( 11): 1490. DOI: 10.3390/molecules21111490.
    [7]
    ZHANG Z, PING J, XU LM. Screening Chinese medicine components for inhibition of human hepatic stellate cell migration[J]. J Clin Hepatol, 2012, 28( 3): 183- 188, 191. DOI: 10.3969/j.issn.1001-5256.2012.03.007.

    张展, 平键, 徐列明. 抑制人肝星状细胞株迁移的中药组分筛选[J]. 临床肝胆病杂志, 2012, 28( 3): 183- 188, 191. DOI: 10.3969/j.issn.1001-5256.2012.03.007.
    [8]
    WANG LF, WANG XN, HUANG CC, et al. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway[J]. Lipids Health Dis, 2017, 16( 1): 82. DOI: 10.1186/s12944-017-0464-z.
    [9]
    KOBYLIAK N, ABENAVOLI L. The role of liver biopsy to assess non-alcoholic fatty liver disease[J]. Rev Recent Clin Trials, 2014, 9( 3): 159- 169. DOI: 10.2174/1574887109666141216102231.
    [10]
    ALAMEDDINE A, FAJLOUN Z, BOURREAU J, et al. The cardiovascular effects of salidroside in the Goto-Kakizaki diabetic rat model[J]. J Physiol Pharmacol, 2015, 66( 2): 249- 257.
    [11]
    WANG SY, ZHAO XX, YANG SX, et al. Salidroside alleviates high glucose-induced oxidative stress and extracellular matrix accumulation in rat glomerular mesangial cells by the TXNIP-NLRP3 inflammasome pathway[J]. Chem Biol Interact, 2017, 278: 48- 53. DOI: 10.1016/j.cbi.2017.10.012.
    [12]
    FAN XJ, WANG Y, WANG L, et al. Salidroside induces apoptosis and autophagy in human colorectal cancer cells through inhibition of PI3K/Akt/mTOR pathway[J]. Oncol Rep, 2016, 36( 6): 3559- 3567. DOI: 10.3892/or.2016.5138.
    [13]
    WANG MH, LUO L, YAO LL, et al. Salidroside improves glucose homeostasis in obese mice by repressing inflammation in white adipose tissues and improving leptin sensitivity in hypothalamus[J]. Sci Rep, 2016, 6: 25399. DOI: 10.1038/srep25399.
    [14]
    GUO Y, WANG SY, YI JJ, et al. Effect of salidroside on apoptosis of CD71+ nucleated red blood cells in bone marrow in high altitude polycythemia model rats[J]. J Jilin Univ(Med Ed), 2023, 49( 5): 1174- 1181. DOI: 10.13481/j.1671-587X.20230510.

    郭勇, 王生艳, 易静静, 等. 红景天苷对高原红细胞增多症模型大鼠骨髓CD71+有核红细胞凋亡的影响[J]. 吉林大学学报(医学版), 2023, 49( 5): 1174- 1181. DOI: 10.13481/j.1671-587X.20230510.
    [15]
    DAI N, ZOU Y, WANG HF, et al. Inhibitory effect of salidroside on liver oxidative stress in rats with non-alcoholic steatohepatitis[J]. Chin J Pathophysiol, 2013, 29( 9): 1704- 1708. DOI: 10.3969/j.issn.1000-4718.2013.09.030.

    戴宁, 邹原, 王慧芳, 等. 红景天苷对非酒精性脂肪性肝炎大鼠肝组织氧化应激的抑制作用[J]. 中国病理生理杂志, 2013, 29( 9): 1704- 1708. DOI: 10.3969/j.issn.1000-4718.2013.09.030.
    [16]
    ZHANG XR. The mechanism of salidroside regulating glucose and lipid metabolism in type 2 diabetes mice through microRNA[D]. Changchun: Jilin University, 2016.

    张新茹. 红景天苷在2型糖尿病小鼠中通过microRNA改善糖脂代谢的机制研究[D]. 长春: 吉林大学, 2016.
    [17]
    WU TF, LIAO XH, ZHONG BH. Epidemiology of nonalcoholic fatty liver disease in some regions of China[J]. J Clin Hepatol, 2020, 36( 6): 1370- 1373. DOI: 10.3969/j.issn.1001-5256.2020.06.039.

    吴挺丰, 廖献花, 钟碧慧. 中国部分地区非酒精性脂肪肝病的流行情况[J]. 临床肝胆病杂志, 2020, 36( 6): 1370- 1373. DOI: 10.3969/j.issn.1001-5256.2020.06.039.
    [18]
    LI YY, XIE ZY. Advances in the etiology and treatment of non-obese nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37( 2): 452- 457. DOI: 10.3969/j.issn.1001-5256.2021.02.043.

    李洋洋, 谢正元. 非肥胖型非酒精性脂肪性肝病的病因及治疗进展[J]. 临床肝胆病杂志, 2021, 37( 2): 452- 457. DOI: 10.3969/j.issn.1001-5256.2021.02.043.
    [19]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [20]
    RONGVAUX A, SHEA RJ, MULKS MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis[J]. Eur J Immunol, 2002, 32( 11): 3225- 3234. DOI: 3.0.CO;2-L">10.1002/1521-4141(200211)32: 11<3225: AID-IMMU3225>3.0.CO;2-L.
    [21]
    KOHJIMA M, HIGUCHI N, KATO M, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease[J]. Int J Mol Med, 2008, 21( 4): 507- 511.
    [22]
    JEON TI, OSBORNE TF. SREBPs: Metabolic integrators in physiology and metabolism[J]. Trends Endocrinol Metab, 2012, 23( 2): 65- 72. DOI: 10.1016/j.tem.2011.10.004.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (277) PDF downloads(32) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return